Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News Can Rubraca really replace docetaxel in prostate cancer? FDA just said yes Rubraca becomes first PARP inhibitor approved before chemo in BRCA+ prostate cancer. Find out how TRITON3 data is reshaping treatment strategy. byVenkateshDecember 22, 2025